what’s next for antibody drug conjugates in urothelial carcinoma?
Published 5 months ago • 73 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
2:30
the future of antibody-drug conjugates in urothelial cancer
-
1:32
antibody-drug conjugates in urothelial carcinoma
-
1:39
utilizing antibody-drug conjugates in the treatment of metastatic urothelial carcinoma
-
0:44
antibody-drug conjugates for advanced bladder cancer
-
1:16
antibody-drug conjugates in advanced urothelial cancer: sacituzumab govitecan
-
5:21
antibody-drug conjugates: a new era in cancer treatment
-
10:11
a brief introduction of antibody drug conjugate - creative biolabs
-
1:07:47
antibodies to watch in 2023
-
2:10
targeting low her2 expression with antibody-drug conjugates
-
2:31
key immunotherapy combinations for urothelial cancer
-
31:39
the evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma
-
40:12
improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates
-
1:33
antibody-drug conjugates (adcs) in nsclc
-
1:20
combining adc’s with other novel agents in the frontline treatment of urothelial carcinoma
-
0:52
what are the latest biomarkers for urothelial carcinoma?
-
2:11
next-generation antibody-drug conjugates in her2 breast cancer
-
3:38
breakthroughs in urothelial cancer treatment at esmo 2023
-
2:03
recent antibody-drug conjugate approvals in gynecologic malignancies
-
6:08
immunotherapy approaches for nmibc
-
1:30
destiny-crc02: antibody-drug conjugates in colorectal cancer
-
6:28
esmo expert report on antibody drug conjugates in the management of urothelial cancer @asco gu 2022
-
1:44
what are antibody-drug conjugates and how do they work against cancer?